Michael Mulroy - Brooklyn Immunotherapeuti Director

BTX
 Stock
  

USD 0.54  0.02  3.85%   

  Director
Mr. Michael H. Mulroy is the Independent Director of BioTime, Inc. Since June 2017, Mr. Mulroy has served as the Chief Executive Officer of Asterias Biotherapeutics, Inc., a publicly traded biotechnology company that is approximately 40 percent owned by BioTime. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC, which assists companies in connection with investor engagement and complex corporate governance issues. Mr. Mulroy served until September 2014 as Executive Vice President Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Mr. Mulroy was appointed Executive Vice President, Strategic Affairs and General Counsel and Corporationrationrate Secretary of Questcor during February 2014, having previously served as Chief Financial Officer, General Counsel and Corporationrationrate Secretary since January 2011. From 2003 to 2011, Mr. Mulroy was employed by the law firm of Stradling Yocca Carlson Rauth, where he served as a partner from 2004, and represented Questcor and other publiclytraded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch. Mr. Mulroy also serves as a director of Asterias Biotherapeutics, Inc. From July 2011 to August 2014, Mr. Mulroy served as a member of the Board of Directors of Comarco, Inc., which developed and designed innovative technologies and intellectual property used in power adapters
Age: 51  Director Since 2014      
212 582 1199  https://www.brooklynitx.com
Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. from the University of Chicago.

Brooklyn Immunotherapeuti Management Efficiency

Brooklyn Immunotherapeuti has Return on Asset of (74.2) % which means that on every $100 spent on asset, it lost $74.2. This is way below average. Brooklyn Immunotherapeuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -24.25 in 2022. Return on Average Assets is likely to drop to -3.2 in 2022. Brooklyn Immunotherapeuti Current Assets are fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Assets of 18.77 Million in 2021. Goodwill and Intangible Assets is likely to rise to about 2.1 M in 2022, whereas Total Assets are likely to drop slightly above 26.9 M in 2022.
The company has 2.72 M in debt with debt to equity (D/E) ratio of 0.42, which is OK given its current industry classification. Brooklyn Immunotherapeuti has a current ratio of 5.0, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brooklyn Immunotherapeuti until it has trouble settling it off, either with new capital or with free cash flow. So, Brooklyn Immunotherapeuti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brooklyn Immunotherapeuti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brooklyn to invest in growth at high rates of return. When we think about Brooklyn Immunotherapeuti's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Ahmet Kent3M Company
2013
Edward Liddy3M Company
2000
Vance Coffman3M Company
2012
Muhtar Kent3M Company
2013
Gregory Page3M Company
2016
Pamela Craig3M Company
2019
Michael Eskew3M Company
2012
Robert Ulrich3M Company
2008
Dambisa Moyo3M Company
2018
Thomas Brown3M Company
2013
Sondra Barbour3M Company
2014
Amy Hood3M Company
2017
David Dillon3M Company
2015
Linda Alvarado3M Company
2000
Herbert Henkel3M Company
2007
Patricia Woertz3M Company
2016
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people. Brooklyn Immunotherapeutics (BTX) is traded on NYSEMKT Exchange in USA. It is located in 10355 Science Center Drive and employs 10 people. Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN. Brooklyn Immunotherapeuti is listed under Pharmaceutical Products category by Fama And French industry classification.

Brooklyn Immunotherapeuti Leadership Team

Elected by the shareholders, the Brooklyn Immunotherapeuti's board of directors comprises two types of representatives: Brooklyn Immunotherapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brooklyn. The board's role is to monitor Brooklyn Immunotherapeuti's management team and ensure that shareholders' interests are well served. Brooklyn Immunotherapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brooklyn Immunotherapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Mulroy, Director
David Schlachet, Director
Stanislaw Pargiela, Member of the Supervisory Board
Michael West, Co-CEO and President and Director
Chase Leavitt, General Counsel and Corporate Secretary
Matt Haines, IR Contact Officer
Don Bailey, Director
Brandi Roberts, CFO, Senior Vice President - Finance
Stephen Cartt, Director
Artur Maczynski, Vice Chairman of the Supervisory Board
Lech Pasturczak, Vice Chairman of the Supervisory Board
Edward Wirth, Other
Stephen Farrell, Independent Director
Tomasz Gierczynski, Chairman of the Management Board
Alfred Kingsley, Chairman of the Board
Judith Segall, VP of Admin., Secretary and Director
Stephana Patton, General Counsel
Deborah Andrews, Director
Dorota Walkiewicz, Member of the Management Board for Administration and Organization
Blazej Wisniewski, Member of the Management Board for Finance, Chief Accounting Officer
David Nakasone, Director - Investor Relations
Jim Knight, Senior Vice President-Head of Corporate Development
Russell Skibsted, CFO
Brian Culley, President CEO, Director
Heinz Jammers, Member of the Supervisory Board
Gary Hogge, Senior Vice President of Clinical & Medical Affairs
Andrzej Pargiela, Secretary of the Supervisory Board
Pedro Lichtinger, CEO of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics Inc
Neal Bradsher, Independent Director
Angus Russell, Director
Aditya Mohanty, Co-CEO
Cavan Redmond, Independent Director
Konrad Kosierkiewicz, Chairman of the Supervisory Board

Brooklyn Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brooklyn Immunotherapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now

   

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
29.7 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.